The QUASAR trial, which evaluated BRAF mutational status as predictive markers for 5‐FU/LV chemotherapy, was unable to detect an association between BRAF mutational status and tumor response to 5‐FU/LV chemotherapy.26 Here, BRAF is linked to neoplasm.